Abbott to Separate Nutrition Unit, Lowers 2026 Sales Growth Outlook
Abbott will separate its Nutrition unit into an independent company by 2027 and lowered its 2026 sales growth outlook to about 6%.
Abbott will separate its Nutrition unit into an independent company by 2027 and lowered its 2026 sales growth outlook to about 6%.
Ionis’s bepirovirsen (Hibsago) is now FDA-approved for chronic hepatitis B. The six-month treatment achieved functional cure in up to 26% of patients, far above standard care.
Fresh ARC-20 data from Arcus show strong PFS and OS for casdatifan in first-, second- and late-line clear cell kidney cancer, per Mizuho.
Amgen and AstraZeneca’s Tezspire showed high histologic remission and symptom improvement in Phase 3 EoE trial, positioning it as a potential Dupixent rival.
Myriad Genetics agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to Labcorp for $210 million, closing by early 2027.
Rapport’s RAP-219 hit key YMRS endpoints in bipolar mania, but agitation imbalance and higher dropouts may cap stock upside, per Wells Fargo.